Treating Bipolar Depression Using Psilocybin—Validity Threats Regarding Efficacy and Safety
Eiko I. Fried, Ioana A. Cristea, Florian Naudet
JAMA Psychiatry April 10, 2024 DOI: 10.1001/jamapsychiatry.2024.0420 via OpenAlex
Summary
AI-generated from the abstractA letter to the editor raises three concerns about a published study that tested 25 mg of psilocybin in 15 patients with treatment-resistant type 2 bipolar depression. The authors of the letter identify specific methodological issues with the study protocol but do not present new data or findings.
Study at a glance
| Characteristics | Letter to the editor Peer reviewed |
|---|---|
| Sample size | 15 |
| Population | Patients with treatment-resistant type 2 bipolar depression |
| Intervention | psilocybin |
| Dose | 25 mg |
| Topics | Psilocybin |
| Keywords | Depression economics Psychiatry Bipolar disorder Hallucinogen |
| Citations | 2 |
| Key finding | The letter identifies three unspecified methodological concerns with the original study's protocol. |
Abstract
To the Editor According to the study protocol, the recently published study by Aaronson et al1 was carried out “to assess effectiveness of 25 mg of psilocybin in [15] patients with treatment-resistant type 2 bipolar depression.” We see 3 concerns.